Royalty Pharma plc (RPRX) Earnings

Management highlights

- Overall Financial and Strategic Performance * Delivered 25th consecutive quarter as a public company with strong predictable double-digit growth, maintaining the company's position as the leading capital allocator in life sciences focused on consistent compounding growth. * Achieved an investment-grade BBB credit rating across all major rating agencies, a major milestone reflecting consistent growth, improved portfolio diversification, and growing cash flows. * Maintains a high-margin, cash-efficient business model, with operating professional costs equaling 4.8% of portfolio receipts in Q2, reflecting ongoing cost savings from the 2025 manager internalization transaction. - Capital Deployment and Shareholder Returns * Deployed $1.1 billion in capital for royalty acquisitions year-to-date 2026, with total announced deal value of $1.7 billion; $349 million in capital was deployed in Q2 primarily for royalty funding and R&D funding for pipeline programs. * Returned ~$370 million to shareholders via dividends and share repurchases in H1 2026, equal to roughly 25% of H1 portfolio cash flow. The weighted average share count declined ~5 million shares (1% YoY) due to the share buyback program. - Portfolio Updates and New Acquisitions * Acquired a 3.75% worldwide royalty on AstraZeneca's Chloramatug, a first-in-class TTR fibril depleting antibody for ATTR-CM, for up to $425 million ($125 million upfront, $125 million due Q1 2027, and up to $175 million in clinical/regulatory milestone payments). Peak annual royalties are expected to be $110-$190 million, with a projected internal rate of return in the teens, aligned with the company's development-stage target range. The acquisition builds on the company's existing ATTR-CM portfolio that already includes Ambutra. * Multiple positive portfolio updates: Revolution Medicines completed rolling submission for Dyrexon Rossi in pancreatic cancer with accelerated review underway in Europe; regulatory approvals were secured for Gilead's Fradelvi, GSK's Gydatro, and Amgen's Simdeltra, which will contribute to top line growth in coming years. * The development-stage pipeline has grown to 19 potential therapies from just 3 at the 2020 IPO, a more than 6-fold increase. Peak potential royalty from the late-stage pipeline now totals ~$2 billion, a more than 30-fold increase since IPO, with a 90% historical approval rate for development-stage investments. * Added industry veteran Greg Raskin to lead the new academic royalty initiative, and hired a top local leader to build out the company's new China market entry effort. - Pipeline Milestones * 2026 has already seen positive clinical readouts and approvals for multiple pipeline assets, including positive trial results for Cytokinetics' Mycorrhizal, Xenacizobaxilumab, and Biogen's Lidofilumab, plus FDA approvals for GSK's Gydatro, Sonali's Avlea, and Gilead's Tredelvi. * Upcoming major pivotal readouts include: 2026 readouts for Novartis' Pellicarsin (cardiovascular disease) and Biogen's Lidofilumab (systemic lupus); 2027 readouts for Dyraxan Raspib (lung cancer), Lidofilumab (cutaneous lupus), Sanofi's Frexalamab (MS), and J&J's Siltarexin (major depressive disorder).

Guidance

- Full year 2026 portfolio receipts guidance was raised for the second consecutive quarter, to a range of $3.4 billion to $3.5 billion, up from the prior range of $3.25 billion to $3.45 billion. This implies gross royalty receipt growth of 7% to 10%, up from the prior guidance of 4% to 8%, reflecting strong underlying portfolio momentum. - The updated guidance already accounts for the loss of exclusivity for Promacta, the launch of biosimilar Tysabri in the U.S., and potential impacts of the IRA. It also expects milestones and other contractual receipts to decline from $128 million in 2025 to ~$60 million in 2026, and does not include any benefit from future royalty acquisitions. - Operating and professional costs are still projected to be 5.5% to 6.5% of 2026 portfolio receipts, in line with prior guidance, reflecting ongoing cost savings from manager internalization. - Full year 2026 interest paid is expected to be $350 million to $360 million, consistent with prior guidance. ~$175 million in interest is expected to be paid in Q3 2026, with a de minimis amount due in Q4 2026. - Management reaffirmed confidence in the long-term guidance of $4.7 billion or more in portfolio receipts by 2030, noting the company is tracking well against this target.

Segment performance

Royalty Pharma reports consolidated segment performance for its biopharma royalty portfolio, with no separate product segment breakdown provided in the call. In Q2 2026: - Portfolio receipts (top line) grew 6% year-over-year to $773 million, beating internal expectations. - Royalty receipts (recurring cash flows, the core portfolio revenue stream) grew 14% year-over-year, driven by strong performances from Tramfaya, Boronigo, Indeltra, and Evrizdi. The business still delivered double-digit royalty growth despite headwinds from Promacta and Imbruvica. - Portfolio cash flow (adjusted EBITDA less net interest paid) totaled $736 million for the quarter, with a 95% cash conversion margin, reflecting the company's high operational efficiency. - Trailing 12-month return on invested capital was 14.2%, and trailing 12-month return on invested equity was 20.1%, marking stable attractive returns. - Total invested capital across the portfolio is ~$22 billion, with 84% allocated to approved products (either approved at investment or development assets that later gained approval), and 12% allocated to development-stage therapies. Roughly one-third of the development-stage capital is invested in programs that already achieved positive pivotal trial results.

Risks & headwinds

No formal material new risks were disclosed in the prepared remarks section. The call notes that all forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially, referencing risk factors disclosed in the company's most recent 10-K filing with the SEC. Development-stage investments carry inherent clinical approval risk, though the company maintains a low overall portfolio exposure to this segment and has a 90% historical approval success rate for its development investments.

Analyst Q&A

• Q: What is Royalty Pharma's outlook on increasing equity use in deal structures amid rising sector M&A, and do lower rates and improved credit ratings make the company more biased to deploy more capital? /

  A: Management says the company has substantial financial flexibility to partner with sellers on whatever deal structure they need to capture opportunities created by sector M&A. Royalty Pharma remains agnostic to the interest rate environment: it deployed significant capital and generated strong returns when rates were rising, and expects to continue generating attractive returns above cost of capital even if rates fall. (287 characters)

• Q: With improved diligence capabilities, will Royalty Pharma increase its allocation to development-stage assets, and what is the update on the company's China market expansion? /

  A: Management says the current 65-35 split of approved to development-stage capital (over a rolling multi-year horizon) will remain broadly stable. Total development-stage allocation as a share of overall invested capital is only 12% today, and management would be comfortable with this trending up to the mid-to-high teens without meaningfully increasing overall portfolio risk. For China, it is early days but the company is fully committed to long-term expansion, has hired a top local leader, and expects the market to become a large long-term opportunity. (473 characters)

• Q: Why do you believe Royalty Pharma's business model and portfolio cannot be replicated even with large amounts of new capital? What explains the low Q2 2026 operating costs and why will costs rise in H2? /

  A: Management says Royalty Pharma's portfolio of unique one-of-a-kind royalty assets, assembled over more than a decade of investments, is impossible to replicate: iconic assets like the Tramfaya and Trilogy royalties are unique and cannot be sourced again today. The development pipeline of future blockbusters also took 5-7 years to assemble, with irreplaceable unique assets. Additional barriers to entry include the company's established scale, low cost of capital, and experienced specialized team, all of which took decades to build. For operating costs, the Q2 decline reflects synergy realization from internalization, and the H2 increase is just standard seasonal variation in cash-based expenses. (562 characters)

• Q: How do you handicap the phase 3 success of Chloramatug based on early phase 1 biomarker data, and how do you avoid adverse selection in R&D co-funding deals? /

  A: Management notes that all prior approved ATTR-CM therapies entered phase 3 based on similar biomarker data, and that biomarker data for Chloramatug clearly shows amyloid clearance from the heart, consistent with the drug's mechanism of action. Positive amyloid depletion data in other amyloid conditions (AL amyloidosis, Alzheimer's) also supports confidence in the program. For R&D co-funding, Royalty Pharma maintains an extraordinarily high investment bar, only pursues the most exciting high-quality assets from partners, and is disciplined about rejecting lower-quality opportunities, avoiding adverse selection. (421 characters) Total characters (excluding headers): 1743